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SUMMARY
Chapter 1 presents an overview of the work contained within this thesis. This chap-
ter contextualises the thesis within Green and Kreuter’s (1999) educational and eco-
logical approach to health promotion planning. It provides a summary of the latest 
epidemiological estimates and projections of the hepatitis C epidemic in Australia and 
contains background information on living with hepatitis C. The chapter then out-
lines the theoretical frameworks and methods used throughout the thesis including a 
discussion of the thesis aims and research questions. Finally, an overview of the main 
findings of the thesis is provided and recent hepatitis C-related psychosocial literature 
is integrated and added to that which appeared in the author’s sociological review of 
literature published in 2003.  
Chapter 2 reviews international and Australian literature related to living with hepati-
tis C infection. At present, scholarly research into this worldwide epidemic focuses on 
medical and scientific understandings of the virus and its effects on people’s health-
related quality of life. Exploration of the socio-cultural impact of hepatitis C infection 
is for the most part absent from this literature. However a nascent academic inquiry 
into living with hepatitis C infection points to a complex range of concerns regarding 
diagnosis, disclosure, stigmatisation and discrimination against people with hepati-
tis C. The increasing association of hepatitis C infection with injecting drug use and 
the medicalisation of those affected by the virus is discussed. This chapter argues for 
an expanded socio-cultural understanding of hepatitis C to account for the material 
effects of medicalisation, stigmatisation and discrimination, and the socio-cultural 
impact of treatment on the lives of people with hepatitis C infection. It concludes with 
suggestions for future directions in social research to address the silence surrounding 
living with hepatitis C infection.      
Chapter 3 reports on a study of people’s experiences of receiving a positive hepati-
tis C diagnosis. To address a paucity of academic literature that described people’s 
experiences of receiving a positive diagnosis, including doctors’ explanation of the 
infection and referral to support services, a cross-sectional study was conducted of 
people with hepatitis C infection living in New South Wales (n=504) during 2001 
and 2002. People diagnosed with non-A non-B hepatitis prior to 1989 when the hep-
atitis C virus was identified were excluded from analysis as it was assumed that these 
people were subjected to different social dynamics to those diagnosed after 1989, by 
which time epidemiology had established that hepatitis C infection was commonly 
associated with injecting drug use. Among participants diagnosed with hepatitis C 
infection after 1989 (n=417), just under a third (29.5%, n=123) reported that they 
had received ‘no explanation’ about their infection from their doctor at diagnosis. 
Women and those diagnosed from 1989 to 1996 – the year before the Australian 
Hepatitis Council was established and commenced publishing informational pam-
phlets – were significantly more likely to report receiving no explanation than men 
and those diagnosed after 1996 (35.4% vs 23.7% and 37.5% vs 23.0% respectively). 
Similarly, current injecting drug users and those diagnosed from 1989 to 1996 were 
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significantly more likely to report receiving no post-test counselling than those who 
were not currently injecting and those diagnosed later (42.9% vs 30.2% and 37.6% 
vs 25.9% respectively). Participants diagnosed from 1997 to 2001 were significantly 
more likely to report receiving pamphlets about hepatitis C infection (39.2% vs 
23.7%), information about treatments (24.5% vs 16.2%) and advice regarding natural 
therapies (9.1% vs 3.8%) than those diagnosed earlier. These data provide evidence of 
an increase in the dissemination of hepatitis C information by doctors at diagnosis, 
during the latter stages of the 1990s. However continued effort is needed to improve 
doctors’ provision of information and referral to specialists and support agencies for 
people newly diagnosed with hepatitis C.   
Chapter 4 presents data regarding hepatitis C-related discrimination. The chapter 
reports findings from a cross-sectional study of people with self-reported hepatitis C 
virus infection (n=504) conducted in New South Wales (NSW), Australia through-
out 2001 and 2002. Participants completed a self-administered questionnaire enquir-
ing into their experience of living with hepatitis C infection. Over a half of all par-
ticipants (57.5%, n=290) reported that they had acquired their infection from inject-
ing drug use. Discrimination was reported by 64.7% (n=326) of participants and 
healthcare was the most commonly reported site where discrimination occurred. A 
logistic regression identified the predictors of any discrimination as: knowing many 
other people with hepatitis C infection (i.e., six or more people); feeling ‘very tired’ 
due to hepatitis C symptoms; and being younger (i.e., less than 51 years). Predictors 
of higher levels of discrimination were: knowing many other people with hepatitis C 
infection (i.e., six or more people); being limited (i.e., either ‘some of the time’ or ‘a 
lot of the time’) in the time spent with family, friends, neighbours and groups due 
to hepatitis C; and feeling pessimistic about hepatitis C treatment and the future 
because of hepatitis C-related ill health. Although discrimination occurred in a range 
of social domains, effort is needed to improve healthcare workers’ service delivery to 
people with hepatitis C infection. Continued discrimination may inhibit people from 
seeking a range of health services and impede efforts to contain the epidemic.      
Chapter 5 presents one of the first published qualitative studies of the experience of 
receiving treatment for hepatitis C infection. Clinical trials of interferon-based treat-
ments for hepatitis C infection show decrements in patients’ health-related quality of 
life due to side effects of therapy. The impact of side effects on patients’ overall qual-
ity of life remains unclear. To explore this issue, people living in New South Wales, 
Australia who had undergone treatment for hepatitis C were interviewed. This chap-
ter reports participants’ experiences of treatment side effects and the impact of the 
therapeutic regimen. This information is important because a new interferon-based 
regimen has been adopted as the mainstay of hepatitis C treatment and it is predicted 
that many more people will seek treatment in Australia. The author argues for further 
qualitative research to enhance knowledge of the impact of this therapy on quality of 
life. 
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Chapter 6 reports on the experience of preparing and managing people throughout 
six or twelve month courses of interferon-based treatment for hepatitis C infection. 
From the clinical literature a high proportion of patients receiving hepatitis C treat-
ment has dose reductions or discontinues treatment because of adverse events arising 
from the therapeutic drugs. Currently there is no published literature which explores 
how health professionals prepare patients for hepatitis C treatment and there is a pau-
city of literature regarding how treatment-related adverse events are managed. Data is 
presented from the author’s exploratory qualitative study which used semi-structured 
in-depth interviews with a sample of health professionals with experience in man-
aging hepatitis C treatment regimens. The study was conducted in Sydney Australia 
throughout 2004 and 2005. The study aimed to report health professionals’ perspec-
tives regarding hepatitis C treatment preparation, and to identify and describe the 
hepatitis C treatment management strategy used by health professionals in this study. 
Participants reported that pre-treatment preparation focused on information provi-
sion regarding adverse events and the medical strategies that could ameliorate their 
impact. Patients’ vulnerabilities and supports were assessed prior to treatment and 
health professionals sought to address patients’ problems as they arose during treat-
ment. Participants discussed patients’ resilient coping style and the beneficial impact 
this had on treatment management. These findings indicate that among this sample 
of health professionals a deficits-based approach was taken to hepatitis C treatment 
management. While some attempts were made to assess patients’ strengths, this 
was limited to identifying those in family, work and social networks who could lend 
support to patients when problems occurred. Exploring patients’ past experiences 
of adversity and making a detailed evaluation of a range of patients’ strengths (i.e. 
strengths-based assessment) might assist clinicians in managing hepatitis C treat-
ment regimens. 
Chapter 7 explores the phenomena of people using illicit drugs while receiving 
hepatitis C treatment from the perspective of one group of health professionals. 
Exploration of patients’ illicit drug use during treatment for hepatitis C virus infec-
tion is largely absent from the clinical literature. Data are presented from a qualitative 
study of health professionals responsible for managing hepatitis C treatment regimens 
at three major metropolitan hospitals across Sydney, Australia. During semi-struc-
tured in-depth interviews participants discussed patients’ use of injected and non-
injected illicit drugs while coping with a demanding therapeutic regimen. Health 
professionals highlighted the socially conservative environment of healthcare and its 
negative perceptions of illicit drug users. Also discussed are the management of peo-
ple who inject during treatment and the efficacy of cannabis to reduce side effects. 
The findings of this study indicate that while the health professionals adopted a harm 
reduction approach to patients’ illicit drug use during HCV treatment, information 
regarding the risks and benefits of illicit drug use is silenced in this context. While 
ever prohibition remains Australia’s illicit drug policy this situation appears unlikely 
to change. Research which investigates the extent of illicit drug use during hepatitis C 
treatment, the risks and benefits associated with their use in this context and the 
harms of perpetuating a duplicitous healthcare system is required.    
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Chapter 8 explores a paradoxical association between social marginalisation and 
positive health outcomes among people receiving treatment for hepatitis C infection. 
In this chapter, participants who were living in socially disadvantaged circumstances 
reported applying adaptive approaches which they had learned from past experiences 
of drug dependence, living with symptoms of chronic illness, coping with depression 
and childhood sexual abuse to enable them to cope with severe treatment-related side 
effects. This finding has implications for the clinical management of hepatitis C treat-
ment; the factors and processes that facilitate adaptive coping to adversity associated 
with social marginalisation can be assessed for their clinical contribution to coping 
with an arduous regimen.  Post-processin
g
